Navigation Links
Crescendo Biologics Announces First 'Triple Knockout' Mouse
Date:9/29/2010

Crescendo Biologics Announces First 'Triple Knockout' Mouse -- CAMBRIDGE, England, September 29, 2010 /PRNewswire/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, New Products & Services, Clinical Trials & Medical Discoveries Click to view news release full screen  

Crescendo Biologics Announces First 'Triple Knockout' Mouse

 

CAMBRIDGE, England, September 29, 2010 /PRNewswire/ --

- Mice Lacking Endogenous Antibody Polypeptides Offer Powerful New Tool for Antibody Fragment Development

Crescendo Biologics Limited (Crescendo) today announces it has established a colony of engineered mice completely devoid of endogenous antibody polypeptides. The proprietary 'triple knockout' mice are believed to be unique and have the immunoglobulin heavy chain (IgH), kappa light chain and lambda light chain loci all functionally silenced by large-scale genomic deletion.

This is a significant advance over previous knockout mice which retain intact lambda light chain. While lambda light chain accounts for at most 10% of the light chains in mouse antibodies, Crescendo believes that knockout of all light chain expression is critical for the efficient generation of human heavy chain antibodies in transgenic mice. The new knockout mouse thus offers an enhanced background for the generation of new antibody therapeutics and is a key step in the establishment of Crescendo's world-leading VH antibody fragment platform. VH fragments are the smallest fragments that retain antibody binding, and have many desirable properties as potential therapeutics.

In a parallel development, Crescendo has also demonstrated the potential of its first generation yeast artificial chromosome (YAC) with the successful expression of human antibodies. Working with Professor Lluis Montoliu at the Centro Nacional de Biotecnologia (a centre belonging to the Spanish National Research Council, CSIC) in Madrid, transgenic mice have been generated by oocyte microinjection with a first YAC comprising several human V genes, all human D and J genes and a C region engineered for expression in the absence of light chains. This YAC has been shown to rearrange and express human antibodies in wild type mice.

"Today's announcement marks an important milestone in the development of our highly innovative antibody fragment technology," said Mike Romanos, CSO of Crescendo Biologics. "We have successfully delivered what we believe to be a unique asset in our triple knockout mice, and have also made significant steps in the generation of YACs which direct the production of human heavy chain antibodies. When combined, and with further developments in our YAC technology, we believe we will have the strongest platform for the generation of new VH fragment therapeutics and can harness the great benefits they will bring as therapeutics."

The Crescendo approach is aimed at bringing together two highly desirable characteristics of antibody platforms - human origin and in vivo maturation - to allow rapid creation of high affinity fragments. The company intends to progress at least one VH-based product to the clinic.

Crescendo is now working to generate mice that combine its newly developed YAC and the triple knockout mouse, in order to generate a first generation Crescendo mouse platform. In addition, Crescendo is generating additional YAC transgenics to progress towards the best in class mouse.

About Crescendo Biologics Ltd

Crescendo Biologics will apply highly innovative antibody fragment technologies to the development of new targeted therapeutics. The Crescendo transgenic mouse platform under development has the potential to rapidly and predictably generate high-affinity human heavy chain antibodies that readily yield VH fragments that have no requirement for humanisation. This is combined with a powerful in vitro ribosome display technology which offers significant advantages over existing approaches in antibody optimisation. VH fragments provide great flexibility as a starting point for the development of new targeted therapeutics combining the specificity and binding affinity of antibodies with certain desirable characteristics of small molecules.

Crescendo's technologies were invented by scientists at the Babraham Institute, Cambridge (UK). The Company has raised GBP4.5 million in seed funding from leading life sciences investors, Sofinnova Partners with Aitua, Avlar BioVentures and the Rainbow Seed Fund also participating. http://www.crescendobiologics.com

Contacts Mike Romanos/Amanda Bettison Crescendo Biologics Tel: +44-(0)1223-497140 Email: mromanos/abettison@crescendobiologics.com Chris Gardner Citigate Dewe Rogerson Tel: +44-(0)207-638-9571 Email: chris.gardner@citigatedr.co.uk
'/>"/>

SOURCE Crescendo Biologics Ltd
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Crescendo Biologics Raises GBP4.5 million in Seed-Funding Led by Sofinnova Partners
2. Immune Biosimilars Will Erode $10.8 Billion in Immune Biologics Brand Sales in 2019 Across the U.S., EU5 and Japan
3. Edimer Pharmaceuticals and CMC Biologics Announce Agreement to Manufacture EDI200 Recombinant Protein
4. Reportlinker Adds Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies
5. Reportlinker Adds Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025 - Opportunities and Challenges in this Emerging Market With High Potential
6. Bone Biologics Announces a Major US Patent Issuance For Its Recombinant Protein Process For the Formation of Cartilage
7. Bone Biologics Announces Another Round of Equity and Debt Investment by Musculoskeletal Transplant Foundation and the Addition of Board Member, Mark Spilker
8. Shire Provides Update on Biologics License Application (BLA) Filing for REPLAGAL(R) (agalsidase alfa) With the U.S. Food and Drug Administration (FDA)
9. In 2012, Stelara and Briakinumab Will Capture 22 Percent of the Biologics Share in the Moderate to Severe Psoriasis Drug Market
10. Dendreon Completes Submission of Biologics License Application for PROVENGE
11. ImaginAb, Inc. and BZL Biologics, LLC Conclude Licensing Agreement for Imaging Rights to huJ591/Prostate-Specific Membrane Antigen (PSMA)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)...  Vermillion, Inc. (NASDAQ: VRML ), a bio-analytical ... formation of the Steering Committee for its Pelvic Mass ... Pelvic masses can present physicians and healthcare professionals ... is ruled out, pelvic masses may include cancers of ... ovarian tumors and gastrointestinal and urinary tract masses. ...
(Date:2/11/2016)... YORK , Feb. 11, 2016  Bioethics International, a ... medicines are researched, developed, marketed and made accessible to patients ... BMJ Open had named the publication of the ... 2015. The publication is also featured as one of ... in the last year that are most frequently read. ...
(Date:2/11/2016)... , Feb. 11, 2016  Wellcentive today ... Portland, Oregon -based community care ... provide population health analytics, quality reporting and care ... FamilyCare strengthen its team of quality managers, analysts ... to the provider groups serving FamilyCare members. ...
(Date:2/11/2016)... CRUZ, Calif. , Feb. 11, 2016  Dovetail ... applications to its beta program for a planned metagenomic ... will present the company,s metagenomic genome assembly method in ... Advances in Genome Biology & Technology conference in ... assembly of these highly complex datasets is difficult. Using ...
Breaking Biology Technology:
(Date:2/1/2016)... , Feb. 1, 2016  Today, the first ... (AHA) announced plans to develop a first of its ... power of IBM Watson. In the first application of ... IBM (NYSE: IBM ), and Welltok will create ... health assessments with cognitive analytics, delivered on Welltok,s health ...
(Date:1/25/2016)... 25, 2016  Glencoe Software, the world-leading supplier of ... industries, will provide the data management solution OMERO Plus ... Photo - ... Phenotypic analysis measures the characteristics and ... comparisons between states such as health and disease, the ...
(Date:1/20/2016)... 20, 2016   MedNet Solutions , an innovative ... of clinical research, is pleased to announce the attainment ... are the result of the company,s laser focus on ... , it,s comprehensive, easy-to-use and highly affordable cloud-based ... Key MedNet growth achievements in 2015 include: ...
Breaking Biology News(10 mins):